Intelligent Bio Solutions Q3 Revenue +46% to $1.06M; Gross Margin 50.5%
Intelligent Bio Solutions reported strong financial results for the fiscal third quarter ended March 31, 2026, with revenue growing 46% year-over-year to $1.06 million. Cartridge sales, a key component of its razor-razorblade model, surged 59% year-over-year and accounted for 66% of quarterly sales. The company also achieved a significant operational milestone with its gross profit margin exceeding 50% for the quarter and improving by 800 basis points for the nine-month period, driven by operational efficiencies and increased sales volumes. Strategic progress included advancing its FDA 510(k) regulatory program for U.S. market entry, establishing a new manufacturing partnership, and securing an eighth European patent.
Key Highlights
- Q3 revenue grew 46% year-over-year to $1.06 million.
- Q3 cartridge sales increased 59% year-over-year to $703,538, representing 66% of revenue.
- Q3 gross profit margin expanded to 50.5%, up from 46.8% in the prior year.
- Nine-month revenue reached $3.07 million, up 39% year-over-year.
- Nine-month gross profit margin improved to 49.3%, up approximately 800 basis points year-over-year.
- Cash and cash equivalents stood at $6.86 million as of March 31, 2026.
- Advanced FDA 510(k) regulatory program for US market entry.
- Secured eighth European patent and new manufacturing partnership.
- Announced drug-testing rollout with Bouygues UK.
Price Impact
More from INBS